A 26-Week Extension Study of the Safety and Clinical Effects of EVP-6124 in Subjects With Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication

Trial Profile

A 26-Week Extension Study of the Safety and Clinical Effects of EVP-6124 in Subjects With Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication

Discontinued
Phase of Trial: Phase III

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Encenicline (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors FORUM Pharmaceuticals
  • Most Recent Events

    • 02 May 2016 Status changed from suspended to discontinued.
    • 14 Sep 2015 Status changed from recruiting to suspended, as per Forum Pharmaceuticals media release.
    • 14 Sep 2015 According to Forum Pharmaceuticals media release, the US FDA has placed clinical hold on all the studies investigating the effect of encenicline in Alzheimer's disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top